Puhr Hannah C, Berchtold Luzia, Zingerle Linda, Korpan Martin, Berger Julia M, Jomrich Gerd, Asari Reza, Schoppmann Sebastian F, Prager Gerald W, Bergen Elisabeth S, Berghoff Anna S, Preusser Matthias, Ilhan-Mutlu Aysegül
Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Christian Doppler Laboratory for Personalized Immunotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Clin Transl Oncol. 2025 Aug 29. doi: 10.1007/s12094-025-04036-3.
History of malignant disease is a common exclusion criterion in clinical cancer trials, yet data on the impact of cancer survivorship on outcome in gastroesophageal cancer patients are scarce.
Retrospective association analyses of self-reported prior or concurrent malignancies with patient characteristics, tumor characteristics, symptoms and overall survival (OS) were performed in 1491 gastroesophageal cancers patients treated between 01/01/2000 and 31/12/2021 at the Medical University of Vienna.
Of 1491 patients 255 (18%) had other primary cancer diagnoses, of which 185 (73%) occurred before, 52 (20%) at the same time as and 18 (7%) both before and at the same time as gastroesophageal cancer diagnosis. 205 (80%) patients had one, 43 (17%) had 2 and 7 (3%) had 3 other malignancies. History of other malignancies was associated with older age (p < 0.0001), squamous cell histology (p = 0.018), less aggressive localized tumor stages (p = 0.037) and fewer acid reflux (p = 0.011). There was neither an association between history of other primary malignancies nor the number of other cancer entities and OS (p = 0.47; p = 0.43).
Self-reported history of other malignant diseases is frequent in a real-life European gastroesophageal cancer cohort and was not statistically significantly associated with outcome, but rather with older age and squamous cell histology. Our data emphasize that cancer survivors should not be categorically excluded from clinical cancer trials due to fear of dismal prognosis. Prospective research is warranted to improve eligibility for this subgroup.
恶性疾病史是临床癌症试验中常见的排除标准,但关于癌症幸存者对食管癌患者预后影响的数据却很少。
对2000年1月1日至2021年12月31日在维也纳医科大学接受治疗的1491例食管癌患者进行回顾性关联分析,分析自我报告的既往或同时发生的恶性肿瘤与患者特征、肿瘤特征、症状和总生存期(OS)之间的关系。
1491例患者中,255例(18%)有其他原发性癌症诊断,其中185例(73%)发生在食管癌诊断之前,52例(20%)与食管癌诊断同时发生,18例(7%)在食管癌诊断之前和同时发生。205例(80%)患者有1种其他恶性肿瘤,43例(17%)有2种,7例(3%)有3种其他恶性肿瘤。其他恶性肿瘤病史与年龄较大(p<0.0001)、鳞状细胞组织学(p=0.018)、侵袭性较小的局部肿瘤分期(p=0.037)和较少的胃酸反流(p=0.011)相关。其他原发性恶性肿瘤病史或其他癌症实体的数量与总生存期之间均无关联(p=0.47;p=0.43)。
在欧洲真实世界的食管癌队列中,自我报告的其他恶性疾病病史很常见,且与预后无统计学显著关联,但与年龄较大和鳞状细胞组织学相关。我们的数据强调,不应因担心预后不佳而将癌症幸存者完全排除在临床癌症试验之外。有必要进行前瞻性研究,以改善该亚组的入选资格。